Who is sponsoring NCT03358628?

NCT03358628 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT03358628?

Interventions in NCT03358628: Molecular Profiling & In Vivo drug testing in PDX.

What condition does NCT03358628 study?

NCT03358628 studies Osteosarcoma.

Is NCT03358628 still recruiting?

NCT03358628 is currently status unknown. Last updated 30 November 2017.

Last reviewed 2017-11-30 · How we verify

NCT03358628

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma

Status unknown Last updated 30 November 2017

What this trial tests

trial testing Molecular Profiling & In Vivo drug testing in PDX in Osteosarcoma in 20 participants. Status unknown.

Timeline

1 February 2018

Primary endpoint
31 January 2020

31 January 2025

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 February 2018
Primary completion	31 January 2020
Estimated completion	31 January 2025

Drugs / interventions tested

Molecular Profiling & In Vivo drug testing in PDX

Conditions studied

Osteosarcoma — all drugs for Osteosarcoma →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 75, any sex, with Osteosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

By obtaining clinical specimens from participants with high-grade bone and soft tissue sarcomas to establish and profile as freshly implanted tumors in mice, the aim of this study is to identify agents with predicted activity in the host patient while also potentially providing them with individualized cancer treatment options

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Patient-derived xenograft models in cancer therapy: technologies and applications.
Liu Y, Wu W, Cai C, Zhang H, et al · · 2023 · cited 290× · PMID 37045827 · DOI 10.1038/s41392-023-01419-2
Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research.
Inoue A, Deem AK, Kopetz S, Heffernan TP, et al · · 2019 · cited 31× · PMID 31500168 · DOI 10.3390/cancers11091321
Patient-derived xenograft model in colorectal cancer basic and translational research.
Liu X, Xin Z, Wang K. · · 2023 · cited 16× · PMID 36543756 · DOI 10.1002/ame2.12299
Functional Drug Screening in the Era of Precision Medicine.
Napoli GC, Figg WD, Chau CH. · · 2022 · cited 16× · PMID 35879922 · DOI 10.3389/fmed.2022.912641
Exploring bone-tumor interactions through 3D <i>in vitro</i> models: Implications for primary and metastatic cancers.
Cristini N, Tavakoli M, Sanati M, Yavari SA. · · 2025 · cited 3× · PMID 40606222 · DOI 10.1016/j.jbo.2025.100698
Combination of Genomic Landsscape and 3D Culture Functional Assays Bridges Sarcoma Phenotype to Target and Immunotherapy.
de Nigris F, Meo C, Palinski W. · · 2023 · cited 3× · PMID 37681936 · DOI 10.3390/cells12172204

Verify or expand the search:

Other recruiting trials for Osteosarcoma

Currently open trials in the same condition.

NCT07479732 — Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma · Phase 1, PHASE2 · recruiting
NCT06935409 — Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-li · Phase 3 · active not recruiting
NCT06521567 — A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer · Phase 1, PHASE2 · active not recruiting
NCT06709495 — Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adol · Phase 1, PHASE2 · recruiting
NCT06541262 — Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors · Phase 1, PHASE2 · recruiting

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03358628 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 30 November 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03358628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing